医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

S2 Genomics Announces Asia-Pacific Distribution Partnerships for the Singulator™ 100 System With SCRUM, PharmiGene, LnCBio, Thunderbio Science, and TrendBio to Accelerate Single-Cell Research

2020年09月10日 AM01:26
このエントリーをはてなブックマークに追加


 

LIVERMORE, Calif.

S2 Genomics, Inc., today announced that it has entered into distribution agreements with SCRUM, PharmiGene, LnCBio, Thunderbio Science, and TrendBio for the promotion, sales, and support of S2’s Singulator™ 100 System and associated products for single-cell genomics and cell biology applications in the Asia-Pacific region.

The distribution agreements cover Japan (SCRUM), South Korea (LnCBio and Thunderbio Science), Taiwan (PharmiGene), and Australia and New Zealand (TrendBio).

“The Asia-Pacific region is experiencing significant growth in single-cell genomic and cell biology analyses, and that is driving a need for improved sample preparation solutions,” said Dr. Stevan Jovanovich, S2 Genomics’ Chief Executive Officer. “We are excited to welcome SCRUM, PharmiGene, LnCBio, Thunderbio Science, and TrendBio as key partners for S2 Genomics. Each of these distributors has significant expertise in life sciences, and especially in genomics. Expanding our commercialization efforts into the Asia-Pacific region represents a significant milestone for S2 Genomics.”

S2 Genomics’ Singulator 100 system enables consistent isolation of single cells or nuclei from solid tissue samples, essential to producing high-quality single-cell data from difficult tissue types. The Singulator 100 system uses single-use disposable cartridges and proprietary reagents to automate tissue dissociation in a convenient workflow. In addition, the system allows users to create their own dissociation protocols, use their own reagents, and dissociate tissue at low temperature to minimize changes to cell transcriptomes.

Takemitsu Furuta, President and CEO of SCRUM noted, “It’s exciting for SCRUM to be working with S2 and expand our product portfolio in cell biology, especially single cell genomics. This is also an important area of current life science studies in Japan. I strongly believe the value of this platform will facilitate our customers’ research studies and greatly improve their experimental efficiency.”

S2 Genomics distributor information can be found at www.S2Genomics.com/distributors.

About S2 Genomics, Inc.

S2 Genomics, founded in 2016, is a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications. S2 Genomics’ technology platforms integrate advanced fluidics, optics, and biochemistry to produce automated sample preparation solutions for single-cell sequencing and cell biology markets, enabling discovery and innovation in life science research, healthcare, and agriculture. For more information, visit https://S2Genomics.com.

For Research Use Only. Not for use in diagnostic procedures.

S2 Genomics, the S2 Genomics logo, and Singulator are trademarks of S2 Genomics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200909005030/en/

CONTACT

Dr. John Bashkin, VP Business Development, S2 Genomics, Inquiries@s2genomics.com

 

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • エクセンシア、2022年第1四半期財務業績を2022年5月25日に報告
  • Anterra Capital:疫情和食品价格通胀激发了投资者对于加快食品和农业部门转型的兴趣
  • サーモの調査で、今年のASCOに参加するがん専門医が最も関心を寄せているのは肺がん・乳がんの新研究であることが判明
  • デンタル・モニタリングが包括的で生涯を通じた患者体験のための仮想診療プラットフォームを発表
  • Dental Monitoring推出虚拟诊疗平台,提供全方位的终身患者体验